By Sufiyan Khan 
Influx Healthtech IPO: Key Dates, Financials, and Investment Potential Explained
The Influx Healthtech IPO has drawn significant attention from investors, thanks to its strong fundamentals, promising financials, and a clear vision for growth. As a leading healthcare contract manufacturing company, Influx Healthtech Limited is tapping into the SME IPO market with a strategic offering aimed at expanding its manufacturing capabilities. Here’s everything you need to know about the Influx Healthtech IPO—from the IPO date and price band to financial highlights and expert reviews.
Influx Healthtech IPO Opens for Subscription
The Influx Healthtech opens for public subscription on June 18, 2025, and closes on June 20, 2025. It is a Book Built Issue aiming to raise approximately ₹58.57 crore, including a fresh issue worth ₹48 crore and an Offer for Sale (OFS) of up to 11,00,400 equity shares with a face value of ₹10 each.
The price band for the Influx Healthtech IPO is set between ₹91 to ₹96 per share. The IPO is set to list on the NSE SME platform on June 25, 2025, with the allotment of shares scheduled for June 23, 2025.
Influx Healthtech IPO: Share Allocation Breakdown
The IPO share allocation is structured as follows:
- Qualified Institutional Buyers (QIBs): 50%
- Non-Institutional Investors (NIIs): 15%
- Retail Investors: 35%
The minimum lot size is 1,200 shares, requiring an investment of ₹1,15,200 at the upper price band. High Net-Worth Individuals (HNIs) need to invest in a minimum of 2 lots (2,400 shares).
About Influx Healthtech Limited
Founded in 2020, Influx Healthtech Limited is a Mumbai-based CDMO (Contract Development and Manufacturing Organization) operating in the healthcare sector. The company has established manufacturing facilities in Thane, Maharashtra, with a total production area exceeding 36,000 sq. ft.
Influx Healthtech manufactures a wide array of products, including:
- Dietary and nutritional supplements
- Herbal and Ayurvedic formulations
- Cosmetics and homecare items
- Veterinary feed supplements
- Active pharmaceutical ingredients (APIs)
The company caters to well-known brands like Bling Brands, Pursuit of Wellness, Novus Life Science, and BigFlex Lifescience. With over 165 permanent employees, Influx Healthtech stands as a reliable partner in contract manufacturing.
Influx Healthtech IPO Financial Performance
The financials of Influx Healthtech reflect steady growth and profitability:
| Financial Year | Revenue (₹ Cr) | Profit (₹ Cr) | Assets (₹ Cr) |
|---|---|---|---|
| 2023 | 76.06 | 7.20 | 28.30 |
| 2024 | 100.10 | 11.22 | 41.10 |
| 2025 | 104.99 | 13.37 | 70.30 |
The company has shown consistent revenue growth and profit margins, which makes the Influx Healthtech IPO appealing for long-term investors.
Influx Healthtech IPO Valuation Metrics
Here are key valuation indicators for FY2025:
- EPS (Earnings Per Share): ₹7.36
- ROE (Return on Equity): 36.98%
- ROCE (Return on Capital Employed): 49.17%
- PAT Margin: 12.75%
- Debt-to-Equity Ratio: 0.01
- Net Asset Value (NAV): ₹19.91
These metrics indicate a well-managed, low-debt company with healthy returns—key factors that make the Influx Healthtech IPO a potentially strong investment.
Influx Healthtech IPO: Use of Proceeds
The funds raised through the Influx Healthtech IPO will be allocated for:
- Setting up manufacturing facilities for the Nutraceutical Division
- Establishing a production unit for Veterinary Food Division
- Purchase of machinery for Homecare and Cosmetic Division
- General corporate purposes
These initiatives underline the company’s commitment to scaling operations and diversifying its product base.
Market Response & Grey Market Premium
The Influx Healthtech IPO has seen robust investor interest, with a subscription rate of 41.07 times by the final day, largely driven by retail and NII categories. According to the grey market, the IPO was commanding a premium of ₹45 to ₹47 per share, suggesting a possible listing gain of up to 49%.
Expert Views on Influx Healthtech IPO
Although major brokerage houses are yet to release in-depth reviews, early opinions from IPO analysts and grey market trends indicate positive sentiment. The company’s strong financials, low debt, and expansion plans have built confidence among retail and institutional investors alike.
Final Verdict: Should You Subscribe to Influx Healthtech IPO?
The Influx Healthtech IPO presents an attractive opportunity for investors looking to gain exposure to India’s expanding healthcare and nutraceutical sector. With consistent revenue growth, strong profit margins, and minimal debt, the fundamentals are solid.
While it is always advisable to consult a financial advisor before investing, early indicators suggest the Influx Healthtech IPO could be a valuable addition to a long-term portfolio.
Read more: Travelers Championship 2025
Sibtain Rizvi
[…] Maoist Encounter: Woman Rebel Shot Dead in Kanker’s Intense Gunfight Influx Healthtech IPO: Date, Price, Allotment, and Expert Review You Need to Know Israel’s Iron Dome Performance Against Iran: Ex-General Reveals Shocking Insights to NDTV […]